CClinicalTrials.gg
CompletedNCT03836274Updated Jan 7, 2020

Tolerance and Acceptability Evaluation of MONACO

An interventional study of AYMES MONACO in Malnutrition, sponsored by Aymes International Limited. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-07.

Sponsored by Aymes International Limited · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Nov 2017, registered Feb 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate tolerance and acceptability of 'MONACO' in patients requiring supplementary oral nutritional support compared with currently available alternatives.

Read the detailed description

To evaluate tolerance and acceptability of 'MONACO' in patients requiring supplementary oral nutritional support compared with currently available alternatives, measuring outcomes of GI effects, Compliance, product preference, convenience etc.

To obtain data to support an ACBS submissions for 'MONACO' (to allow for prescription in the community at NHS expense).

02

Conditions studied

  • Malnutrition

Browse trials for

03

In context

Malnutrition

1,587 studies on the registry are indexed under Malnutrition; 237 are open to participants now.

This study's enrollment of 15 is below the median of 90 across 1,134 interventional studies indexed under Malnutrition.

Browse Malnutrition studies →

Lead sponsor

Aymes International Limited is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients (>18 years) who are able to communicate clearly.
  • Patients with or at risk of malnutrition as determined by growth charts and/or by professional clinical judgement.
  • Patients expected to require oral nutritional supplementation for at least 2 further weeks.
  • Patients requiring supplementary intake approximately 300 kcal /day from an oral nutritional supplement
  • Informed assent/consent obtained.

Exclusion criteria

Exclusion Criteria:

  • Patients with cow's milk protein allergy requiring a milk free diet
  • Patients with inherited metabolic conditions.
  • Patients requiring enteral tube feeding or parenteral nutrition.
  • Patients with medical or dietary contraindication to any feed ingredients (see appendix 2 for full ingredient list)
  • Patients with significant renal (requiring dialysis) or hepatic impairment (e.g. hepatitis)
  • Patients with dysphagia requiring stage 1, 2 or 3 thickened fluids.
  • Patients with uncontrolled inflammatory bowel disease or previous bowel resection with ongoing gastrointestinal symptoms.
  • Patients for whom the investigator has concerns regarding the ability or willingness of the patient and or carer to comply with protocol requirements
  • Participation in any other studies involving investigational or marketed products concomitantly or within 2 weeks prior to entry into the study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Experimental

    Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'MONACO' for a period of 9 days.

    Dietary Supplement: AYMES MONACO

Interventions

  • Dietary supplementAYMES MONACO

    AYMES MONACO is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.

06

What researchers measure

Primary outcomes

  1. GI Tolerance

    To assess gastro-intestinal tolerance of 'MONACO' in patients in the community requiring oral nutritional supplementation. Monitoring includes recording the number and consistency of bowel movements, any episodes of nausea, vomiting, abdominal pain, bloating or diarrhoea.

    Time frame: 9 Days

Secondary outcomes

  1. Acceptability and Palatability of Consuming the Nutritional Supplement: questionnaire

    To assess the acceptability of 'MONACO' in patients in the community requiring oral nutritional supplementation. At the end of the intervention period an acceptability and preference questionnaire will be completed by the patient in order to seek their opinion on the taste, smell, texture and overall liking of the new supplement drink. A 5 point hedonic scale will be used.

    Time frame: 9 days

07

Study locations

1 site
  • AYMES International
    Haywards Heath, RH16 9PL, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03836274
Lead sponsor
Aymes International Limited
Responsible party
Sponsor
First posted
Feb 11, 2019
Start date
Nov 1, 2017
Primary completion
Jan 1, 2020
Completion
Jan 1, 2020
Last update
Jan 7, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion